Equities

Shanghai Haohai Biological Technology Co Ltd

Shanghai Haohai Biological Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)58.83
  • Today's Change-12.07 / -17.02%
  • Shares traded220.60k
  • 1 Year change-18.52%
  • Beta1.6795
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.

  • Revenue in CNY (TTM)2.75bn
  • Net income in CNY430.21m
  • Incorporated2007
  • Employees2.16k
  • Location
    Shanghai Haohai Biological Technology Co Ltd4F, No 2 Building, Alley 139Anshun Road, Changning DistrictSHANGHAI 200336ChinaCHN
  • Phone+86 2 152293555
  • Fax+86 2 152293558
  • Websitehttps://www.3healthcare.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qingdao Haier Biomedical Co Ltd2.24bn358.01m11.69bn2.64k32.632.72--5.231.131.137.0413.530.40185.126.38848,473.706.5611.498.2915.2247.8249.9816.3425.202.53--0.031626.53-20.3622.07-32.4128.9420.64--
Beijing Wandong Medical Technolgy Co Ltd1.40bn184.09m12.17bn1.06k66.072.57--8.670.2620.2622.006.740.26472.764.011,325,746.003.505.303.916.2138.8345.2113.2216.469.48--0.017935.8210.305.327.514.22-16.665.39
Shandong Weigao Orthopaedic Devce Co Ltd1.28bn154.60m12.19bn2.21k79.003.12--9.490.38580.38583.209.780.25240.67144.03581,131.603.1410.973.9513.6962.4077.3312.4327.083.62--0.009617.90-30.551.17-79.36-19.11-4.31--
Shanghai Runda Medical Technology Co Ltd8.43bn40.27m13.18bn3.32k326.803.07--1.560.06730.067313.617.170.58314.191.492,543,990.001.184.783.1312.8625.9427.132.036.361.013.040.560912.43-12.848.93-34.580.85143.881.03
Shanghai MicroPort Edvcl MdTch Grp CoLtd1.27bn657.34m13.61bn908.0020.303.50--10.735.445.4410.5931.540.3711.336.511,396,816.0019.0017.6821.5519.4374.5176.6051.2142.255.49--0.006744.4632.4338.7237.9840.2850.18--
Sansure Biotech Inc1.41bn259.42m13.73bn2.01k52.671.87--9.760.44750.44752.4412.620.16670.8782.03701,473.702.5226.742.7930.9776.4367.4715.1242.017.45--0.058322.40-84.3927.12-81.22121.8964.08--
Micro-Tech Nanjing Co Ltd2.68bn550.49m14.58bn2.40k26.403.91--5.442.942.9414.3019.860.61181.656.801,114,222.0012.8710.7415.2612.8266.0463.0421.0419.373.99--0.018335.4321.7821.2046.9920.3239.33--
Shanghai Haohai Biological Tech Co Ltd2.75bn430.21m14.89bn2.16k38.092.95--5.421.861.8611.8924.070.38331.607.601,272,966.005.604.846.605.5068.9772.0414.6116.363.71--0.069736.8624.5911.24130.580.076211.96--
Beijing Balance Medical Technolgy Co Ltd405.57m103.55m17.14bn473.00165.6914.63--42.270.75310.75312.968.530.31831.094.94857,444.607.148.067.468.4088.3189.4122.4230.028.22--0.009169.1925.5727.3521.0928.10125.94--
Data as of Sep 13 2024. Currency figures normalised to Shanghai Haohai Biological Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.81%Per cent of shares held by top holders
HolderShares% Held
Hwabao WP Fund Management Co., Ltd.as of 30 Jun 20242.48m1.28%
Bosera Asset Management Co., Ltd.as of 30 Jun 20241.49m0.77%
Penghua Fund Management Co., Ltd.as of 30 Jun 2024689.77k0.36%
The Vanguard Group, Inc.as of 02 Oct 2024545.33k0.28%
GF Fund Management Co., Ltd.as of 30 Jun 2024492.15k0.25%
Guotai Asset Management Co., Ltd.as of 30 Jun 2024424.91k0.22%
China Southern Asset Management Co., Ltd.as of 30 Jun 2024356.17k0.18%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024330.19k0.17%
China Asset Management Co., Ltd.as of 30 Jun 2024310.14k0.16%
Yinhua Fund Management Co., Ltd.as of 30 Jun 2024272.89k0.14%
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.